Is Biogen Idec Inc. (BIIB) Going to Burn These Hedge Funds?
To most traders, hedge funds are assumed to be worthless, outdated financial tools of years past.
Posts Tagged ‘NASDAQ:BIIB’
Do Hedge Funds and Insiders Love Celgene Corporation (CELG)?
Celgene Corporation (NASDAQ:CELG) was in 44 hedge funds' portfolio at the end of the first quarter of 2013.
Amgen, Inc. (AMGN) Stock Checkup for May
I have jokingly referred to Amgen, Inc. (NASDAQ:AMGN) in the past as a "senior citizen" of biotech. The company was founded 33 years ago, making Amgen, Inc.
Hedge Funds Are Betting On Gilead Sciences, Inc. (GILD)
To the average investor, there are a multitude of indicators market participants can use to watch stocks.
PDL BioPharma Inc. (PDLI), AbbVie Inc (ABBV): Two Scariest Dividend Stocks in Health Care
Combining nice dividends with a growing industry that comprises roughly one-fifth of the nation's GDP should make for an attractive stock -- in theory.
Visa Inc (V), Alliance Data Systems Corporation (ADS) & More: Navellier & Associates’ Top Portfolio Holdings
With roughly $2.5bn in assets under management, Navellier & Associates is a team of about twelve investment professionals that use quantitative and fundamental analysis to employ...
Celgene Corporation (CELG), Biogen Idec Inc. (BIIB), Gilead Sciences, Inc. (GILD): Don’t Try to Pick the Best Biotech Company
Rising biotech stars Celgene Corporation (NASDAQ:CELG), Biogen Idec Inc. (NASDAQ:BIIB), and Gilead Sciences, Inc.
Biogen Idec Inc. (BIIB) Bounces Higher
If you thought that the great run so far in 2013 was over for Biogen Idec Inc. (NASDAQ:BIIB), think again.
Johnson & Johnson (JNJ): Buying Isn’t for Growth Investors
If there's one health-care stock every investor knows by name, it's Johnson & Johnson (NYSE:JNJ).
Gilead Sciences, Inc. (GILD) or Biogen Idec Inc. (BIIB)? This Is What the Perfect Biotech Would Look Like
I don't know about you, but I'm pretty stoked for the NFL draft this Thursday.
Eli Lilly & Co. (LLY), WellPoint, Inc. (WLP) & Five Must-Watch Earnings Reports in the Health-Care Sector This Week
If you haven't noticed, it's earnings season once again! Believe it or not, there are times when earnings reports slow down in frequency, but this is certainly not one of those...
Why Elan Corporation, plc (ADR) (ELN) Shouldn’t Take Royalty Pharma’s Sweetened Bid
After years of being plagued by a waning stock price, FDA regulatory issues and safety concerns over its blockbuster drug, its finally good to be Elan Corporation, plc (ADR) (...
Biogen Idec Inc. (BIIB), Pharmacyclics, Inc. (PCYC), Immunomedics, Inc. (IMMU), and Tackling Cancer, Non-Hodgkin Lymphoma’s Biggest Current & Upcoming Players
As I noted seven weeks ago, cancer statistics are both staggering and disappointing.
Under The Hood: An Unheralded Biotech ETF – iShares NASDAQ Biotechnology Index (IBB)
Another day, another set of fresh all-time highs for the major biotechnology ETFs.
Arena Pharmaceuticals, Inc. (ARNA), Biogen Idec Inc. (BIIB): More Than an Obesity Drug Company
Arena Pharmaceuticals, Inc.
Amgen, Inc. (AMGN): The One Biotech Stock Buffett Should Buy
The biotechnology sector can be a land of immense spoils and incredible heartbreak.
Johnson & Johnson (JNJ), Rigel Pharmaceuticals, Inc. (RIGL): This Week in Biotech
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Biogen Idec Inc. (BIIB), United Therapeutics Corporation (UTHR), Repros Therapeutics Inc (RPRX): This Week in Biotech
With the SPDR S&P Biotech (ETF) (NYSEARCA:XBI) Index up 25% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector...
Biogen Idec Inc. (BIIB), Sanofi SA (ADR) (SNY), Elan Corporation, plc (ADR) (ELN): The Greatest Thing Since Sliced Bread Has Arrived for MS Patients
Last November, I examined five experimental drugs that appeared as if they had all of the tools necessary to become life-changing blockbusters from a financial and quality of ...
Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Is Amgen, Inc. (AMGN) a Cash King?
In this series, we'll highlight four companies in an industry, and compare their "cash king margins" over time, trying to determine which has the greatest likelihood of putting...
Abbott Laboratories (ABT), Biogen Idec Inc. (BIIB): Will Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Help You Retire Rich?
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Pfizer Inc. (PFE), Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Decision Looms on New Multiple Sclerosis Drug
Will good news from Europe echo on this side of the Atlantic within the next few days? Biogen Idec Inc. (NASDAQ:BIIB) is certainly hoping so.
This Metric Says You Are Smart to Sell Biogen Idec Inc. (NASDAQ:BIIB)
Is Biogen Idec Inc. (NASDAQ:BIIB) an attractive investment right now? The best stock pickers are becoming less hopeful.
Better Biotech Buy: Biogen Idec Inc. (BIIB) vs. Celgene Corporation (CELG)
Buying big pharma stocks isn't the only way you can invest in today's best-selling drugs without taking a gamble on a small, risky biotech.
The Fight Over This Biotech’s Cash: Elan Corporation, plc (ADR) (ELN)
Elan Corporation, plc (ADR) (NYSE:ELN) was nice enough to give us a little more detail on what it plans to do with the $3.25 million that the biotech stands to get from Biogen...
Elan Corporation, plc (ADR) (ELN) Received Buyout Bid Before Buyback
When Elan Corporation, plc (ADR) (NYSE:ELN) sold its stake in the blockbuster selling multiple sclerosis drug Tysabri to partner Biogen Idec Inc.
Caterpillar Inc. (CAT)’s Earnings Weigh Down the Dow
Seems like every day now the Dow Jones Industrial Average is touching a new yearly high. As of 2:25 p.m.
Biogen Idec Inc. (BIIB): A Strong Growth Opportunity In Multiple Sclerosis
Biogen Idec Inc.(NASDAQ:BIIB) has just moved to reinforce its dominance in the multiple sclerosis treatment market by striking a deal to buy the 50% rights to Tysabri that it...
Spectrum Pharmaceuticals, Inc. (SPPI) Earnings: An Early Look
Earnings season is now starting to wind down, with most companies already having reported their quarterly results.
Celgene Corporation (CELG): My Favorite Big Biotech for 2013
The biggest biopharmaceutical companies blazed trails and lifted portfolios last year.
Amgen, Inc. (AMGN)’s Future Is Brighter Than You Might Think
When you think about a cutting-edge, one-foot-in-the-future biotech company, no one would blame you for skipping over Amgen, Inc. (NASDAQ:AMGN).
Will Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Rule This Multibillion-Dollar Market?
Back in 2011, generic drug giant Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) dominated the MS field, riding the coattails of its Copaxone medication to success.
Why Elan Corporation, plc (ELN) Cut Its Ties To Tysabri
Elan Corporation, plc (NYSE:ELN) just announced a restructuring of its Tysabri collaboration with Biogen Idec Inc.
Has Elan Corporation, plc (ADR) (ELN) Become the Perfect Stock?
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
This Week in Biotech: Celgene Corporation (CELG) Biogen Idec Inc. (BIIB)
With the SPDR S&P Biotech Index up 21% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Today’s 3 Best Stocks: Microchip Technology Inc. (MCHP), Biogen Idec Inc. (BIIB), Yum! Brands, Inc. (YUM)
On the economic data front, China reported a 12.4% surge in exports in January, and Germany recorded its second-largest trade surplus in the past 60 years, signaling that both...
A Generic Double Whammy: Teva Pharmaceutical Industries Ltd (TEVA), Mylan Inc. (MYL)
Its narcolepsy drug Provigil saw generic competition from Par Pharmaceutical Companies, Inc. (NYSE:PRX) and Mylan Inc.
A Win-Win Multiple Sclerosis Deal? – Biogen Idec Inc. (BIIB), Elan Corporation, plc (ELN)
Biogen Idec Inc. (NASDAQ:BIIB) is buying the full rights to multiple sclerosis drug Tysabri from Elan Corporation, plc (ADR) (NYSE:ELN) for $3.25 billion.
Teva Pharmaceutical Industries Ltd (TEVA) Earnings: An Early Look
Earnings season is in full swing, with huge numbers of companies having already given their latest numbers to investors.
